This company has taken a deliberately premium culinary route, commercialising cultivated meat first as “new” gourmet items (including pâté/foie-gras-style products) derived from Japanese quail cells. Its target market is high-end foodservice where novelty and price points can better match early production economics.
The company describes starting from animal cells and cultivating them, then combining the cultivated component with chef-recognisable ingredients to reach specific taste/texture goals. Media reporting also describes its bioreactor-led production platform and the strategic choice to lean into luxury rather than “chicken nugget” commodity categories initially.
Commercial stage: regulators in Australia (via Food Standards Australia New Zealand) approved its products for sale, and reporting indicates menu rollouts in Australian fine dining shortly after approval, complementing earlier Singapore availability for its quail-based offerings.
Availability: described as available in Singapore through high-end venues and expanding through Australian restaurants post-approval (not mass retail).
Timeline and regions: near-term focus is approved markets (Singapore, Australia/NZ); other regions (notably the US) remain contingent on regulatory filings and review timelines.